Načítá se...
Ipilimumab: from preclinical development to future clinical perspectives in melanoma
The arsenal for the treatment of metastatic melanoma is limited. A new approach to therapy using checkpoint blockade has improved overall survival in this patient population. Ipilimumab a CTLA-4 monoclonal antibody is a first in class drug that has pioneered this revolution. In this review, the auth...
Uloženo v:
| Vydáno v: | Future Oncol |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Future Medicine Ltd
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5618953/ https://ncbi.nlm.nih.gov/pubmed/27882779 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon-2016-0385 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|